Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05477823 · ClinicalTrials.gov registry record · Early Phase 1
Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer
A Early Phase 1 study of Prostate Cancer, sponsored by University of Wisconsin, Madison.
- Active
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05477823 is a Early Phase 1 study of Prostate Cancer that is active but no longer recruiting, run by University of Wisconsin, Madison. The registered enrollment target is 30 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05477823, a Early Phase 1 study of Prostate Cancer, is active but no longer recruiting, sponsored by University of Wisconsin, Madison.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the imaging and gene expression biomarkers in prostate cancer. Participants have high-risk prostate cancer and have indicated they will undergo external beam radiation therapy, brachytherapy, and androgen deprivation therapy (EBRT+BTX+ADT). Participants can expect to be in this study for up to 5 years.
Conditions Studied
Interventions
- RADIATION External beam radiation therapy
- RADIATION Prostate brachytherapy boost
- DRUG Androgen deprivation therapy
- DIAGNOSTIC_TEST Positron emission tomography (PET)/magnetic resonance imaging (MRI)
Study Locations (1)
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-03-08 |
| Est. Completion | 2027-08 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05477823
The ClinicalTrials.gov registry entry for NCT05477823 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower). The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which External beam radiation therapy is the first listed.
NCT05477823 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT05477823 about?
NCT05477823 is a clinical study titled "Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer". The purpose of this study is to evaluate the imaging and gene expression biomarkers in prostate cancer. Participants have high-risk prostate cancer and have indicated they will undergo external beam radiation therapy, brachytherapy, and androgen deprivation therapy (EBRT+BTX+ADT). Participants can e...
What is the current status of trial NCT05477823?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2023-03-08. Estimated completion is 2027-08.
What conditions does trial NCT05477823 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT05477823?
The interventions under investigation include: External beam radiation therapy (RADIATION), Prostate brachytherapy boost (RADIATION), Androgen deprivation therapy (DRUG), Positron emission tomography (PET)/magnetic resonance imaging (MRI) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05477823?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05477823 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study
RECRUITING · Early Phase 1
-
Pilot Study of (MR) Imaging with Pyruvate (13C) to Detect High Grade Prostate Cancer
RECRUITING · Early Phase 1
-
A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer
RECRUITING · Early Phase 1
-
Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients
RECRUITING · Early Phase 1
-
Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT
RECRUITING · Early Phase 1
-
Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer
ACTIVE NOT RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.